CDK4 and breast carcinoma: CDK4/6 inhibitors (CDK4/6i) have emerged as first-line therapeutic strategies for metastatic hormone receptor-positive (HR+) breast cancer and demonstrate promising potential in other malignancies such as non-small-cell lung cancer and melanoma11–13.